Laurent Cotte1,2, Eric Cua3, Jacques Reynes4,5, François Raffi6,7, David Rey8, Pierre Delobel9,10,11, Amandine Gagneux-Brunon12, Christine Jacomet13, Romain Palich14, Hélène Laroche15,16,17, André Cabie18,19,20, Bruno Hoen21,22,23, Christian Chidiac1,24, Pierre Pradat25. 1. Department of Infectious Diseases, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon. 2. INSERM U1052, Lyon. 3. Department of Infectious Diseases, Hôpital l'Archet, Centre Hospitalier Universitaire de Nice, Nice. 4. Department of Infectious Diseases, Centre Hospitalier Universitaire de Montpellier, Montpellier. 5. INSERM U1175, UMI 233, Université de Montpellier, Montpellier. 6. Department of Infectious Diseases, Hotel-Dieu Hospital, Centre Hospitalier Universitaire de Nantes, Nantes. 7. INSERM CIC 1413, Nantes. 8. HIV Infection Care Centre, Hôpitaux Universitaires, Strasbourg. 9. Department of Infectious Diseases, Centre Hospitalier Universitaire de Toulouse, Toulouse. 10. INSERM, UMR1043, Toulouse. 11. Université Toulouse III Paul Sabatier, Toulouse. 12. Department of Infectious Diseases, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne. 13. Department of Infectious Diseases, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand. 14. Department of Infectious Diseases, Pitié-Salpêtrière Hospital, Assistance Publique - Hôpitaux de Paris, Paris. 15. Service d'Immuno-Hématologie clinique, APHM Hôpital Sainte-Marguerite, Marseille. 16. Aix-Marseille University. 17. INSERM U912 (SESSTIM), Marseille. 18. Department of Infectious Diseases, Centre Hospitalier Universitaire de Martinique, Fort, de France. 19. Université des Antilles EA4537, Fort, de France. 20. INSERM CIC1424, Fort-de-France. 21. Service de Maladies Infectieuses et Tropicales, Dermatologie et Médecine Interne, Centre Hospitalier Universitaire de Pointe-à-Pitre, Pointe-à-Pitre. 22. Faculté de Médecine Hyacinthe Bastaraud, Université des Antilles, Pointe-à-Pitre. 23. INSERM CIC 1424, Pointe-à-Pitre. 24. Université, Claude Bernard Lyon 1, Lyon. 25. Center for Clinical Research, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France.
Abstract
BACKGROUND & AIMS: HCV incidence still appears on the rise in HIV-infected MSM in France. We assessed the incidence of HCV infection in HIV-positive and in preexposure prophylaxis (PrEP)-using MSM. METHODS: HIV-infected, HCV-negative MSM with serological follow-up in 2016 and HIV-negative, HCV-negative PrEP-using MSM enrolled from January 2016 to May 2017 in the French Dat'AIDS cohort were analyzed to assess the incidence of a primary HCV infection. The incidence of HCV reinfection was also determined in patients having cured a previous infection. RESULTS: Among 10,049 HIV-infected MSM followed in 2016, 681 patients were already HCV-infected when entering the study (prevalence 6.8%). Serological follow-up was available in 2016 for 4,151 HCV-negative patients. Virological follow-up was available for 478 patients who had cured a previous infection. Fifty-seven HCV infections occurred in 2016 (42 primary infections, 15 reinfections). Incidence of primary HCV infection, reinfection and overall HCV infection was respectively 1.0, 3.1 and 1.2/100 person-years (PY). From January 2016 to May 2017, 930 HIV-negative subjects were enrolled for PrEP. Seventeen patients were already HCV-infected (prevalence 1.8%). Twelve HCV infections occurred during follow-up (10 primary infections, 2 reinfections) giving an incidence of primary infection of 1.0/100 PY and an overall incidence of 1.2/100 PY. CONCLUSIONS: The overall incidence of HCV infection and of a primary HCV infection in HIV-positive and in PrEP-using MSM appeared similar in France in 2016-early 2017. HIV-positive and PrEP-using MSM probably share similar at-risk practices and both should be targeted for preventative interventions. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
BACKGROUND & AIMS: HCV incidence still appears on the rise in HIV-infected MSM in France. We assessed the incidence of HCV infection in HIV-positive and in preexposure prophylaxis (PrEP)-using MSM. METHODS:HIV-infected, HCV-negative MSM with serological follow-up in 2016 and HIV-negative, HCV-negative PrEP-using MSM enrolled from January 2016 to May 2017 in the French Dat'AIDS cohort were analyzed to assess the incidence of a primary HCV infection. The incidence of HCV reinfection was also determined in patients having cured a previous infection. RESULTS: Among 10,049 HIV-infected MSM followed in 2016, 681 patients were already HCV-infected when entering the study (prevalence 6.8%). Serological follow-up was available in 2016 for 4,151 HCV-negative patients. Virological follow-up was available for 478 patients who had cured a previous infection. Fifty-seven HCV infections occurred in 2016 (42 primary infections, 15 reinfections). Incidence of primary HCV infection, reinfection and overall HCV infection was respectively 1.0, 3.1 and 1.2/100 person-years (PY). From January 2016 to May 2017, 930 HIV-negative subjects were enrolled for PrEP. Seventeen patients were already HCV-infected (prevalence 1.8%). Twelve HCV infections occurred during follow-up (10 primary infections, 2 reinfections) giving an incidence of primary infection of 1.0/100 PY and an overall incidence of 1.2/100 PY. CONCLUSIONS: The overall incidence of HCV infection and of a primary HCV infection in HIV-positive and in PrEP-using MSM appeared similar in France in 2016-early 2017. HIV-positive and PrEP-using MSM probably share similar at-risk practices and both should be targeted for preventative interventions. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
Authors: Natasha K Martin; Klaus Jansen; Matthias An der Heiden; Christoph Boesecke; Anders Boyd; Knud Schewe; Axel Baumgarten; Thomas Lutz; Stefan Christensen; Alexander Thielen; Stefan Mauss; Jürgen K Rockstroh; Britt Skaathun; Patrick Ingiliz Journal: J Infect Dis Date: 2019-10-08 Impact factor: 5.226
Authors: Stephanie Popping; Sebastiaan J Hullegie; Anne Boerekamps; Bart J A Rijnders; Robert J de Knegt; Jürgen K Rockstroh; Annelies Verbon; Charles A B Boucher; Brooke E Nichols; David A M C van de Vijver Journal: PLoS One Date: 2019-01-10 Impact factor: 3.240
Authors: Bernadien M Nijmeijer; Julia Eder; Catharina J M Langedijk; Tanja M Kaptein; Sofie Meeussen; Pascale Zimmermann; Carla M S Ribeiro; Teunis B H Geijtenbeek Journal: Front Immunol Date: 2020-03-27 Impact factor: 7.561
Authors: Jason J Ong; Rachel C Baggaley; Teodora E Wi; Joseph D Tucker; Hongyun Fu; M Kumi Smith; Sabrina Rafael; Vanessa Anglade; Jane Falconer; Richard Ofori-Asenso; Fern Terris-Prestholt; Ioannis Hodges-Mameletzis; Philippe Mayaud Journal: JAMA Netw Open Date: 2019-12-02